News

Public · Published

Canaccord Genuity maintains Travere Therapeutics at Buy, raises price target to $72 from $70

Canaccord Genuity maintained its Buy rating on Travere Therapeutics and raised its price target to $72 from $70, a 2.9% increase. The target represents 37.4% upside from the stock's November 4 closing price of $52.42.

Published:

Updated:

What happened

Canaccord Genuity maintained its Buy rating on Travere Therapeutics and raised its price target to $72 from $70, a 2.9% increase. The target represents 37.4% upside from the stock’s November 4 closing price of $52.42.

Confirmed

Global impact / market context

The higher target signals that Canaccord sees more potential value in Travere shares while keeping its positive rating. If investors act on that view, buying could support the share price, but the target is an analyst estimate, not a guaranteed return or company forecast.

Analyst inference

The update is an analyst rating change, not news about Travere’s sales, costs, cash available, or clinical and regulatory progress. Its immediate relevance is therefore investor positioning: the $72 target offers a reference point for comparing expectations with the $52.42 November 4 close.

Analyst inference

What to watch

  1. Watch for later Canaccord updates to the Buy rating or $72 target, which would show whether the firm continues to hold this view. Analyst inference
  2. Compare Travere’s future reported results and company updates with the assumptions investors may attach to the analyst’s higher target. Analyst inference
  3. The article reports a 37.4% implied upside from the November 4 close; this is calculated from the target and that past closing price. Confirmed

Evidence

  • Original source link unavailable